{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-122724","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.110147+00:00","generated_at":"2026-05-16T12:32:18.420436+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Altimmune reports positive 48-week IMPACT data; FDA agrees on Phase 3 path for pemvidutide","bullets":["Pemvidutide 1.8 mg reduced ELF by -0.58 (p<0.0001) and LSM by -3.97 (p<0.001) vs placebo at 48 weeks.","Weight loss of 7.5% (1.8 mg, p<0.0001) vs 0.2% placebo; no plateau at 48 weeks; AE discontinuation 1.2% vs 3.5%.","Proportion achieving both ELF ≥0.5 reduction and LSM ≥30% reduction: 32.4% (1.8 mg) vs 3.2% placebo (p<0.0001).","End-of-Phase 2 FDA meeting on Dec 11 aligned on Phase 3 design; FDA open to AIM-MASH AI tool; plan to evaluate 2.4 mg dose.","Altimmune raised ~$54.6M net from ATM sales of 13.5M shares after Sep 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-122724","json":"https://secwatch.observer/filing/0001104659-25-122724.json","markdown":"https://secwatch.observer/filing/0001104659-25-122724.md","text":"https://secwatch.observer/filing/0001104659-25-122724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000110465925122724/0001104659-25-122724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000110465925122724/tm2533869d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:32:18.420436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}